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A B S T R A C T
Purpose
Neoadjuvant chemotherapy followed by radical cystectomy (RC) is a standard of care for the
management of muscle-invasive bladder cancer (MIBC). Dose-dense cisplatin-based regimens have
yielded favorable outcomes compared with standard-dose chemotherapy, yet the optimal neo-
adjuvant regimen remains undeﬁned. We assessed the efﬁcacy and tolerability of six cycles of
neoadjuvant dose-dense gemcitabine and cisplatin (ddGC) in patients with MIBC.
Patients and Methods
In this prospective, multicenter phase II study, patients received ddGC (gemcitabine 2,500 mg/m2
on day 1 and cisplatin 35 mg/m2 on days 1 and 2) every 2 weeks for 6 cycles followed by RC. The
primary end point was pathologic downstaging to non–muscle-invasive disease (, pT2N0). Patients
who did not undergo RC were deemed nonresponders. Pretreatment tumors underwent next-
generation sequencing to identify predictors of chemosensitivity.
Results
Forty-nine patients were enrolled from three institutions. The primary end point was met, with 57%
of 46 evaluable patients downstaged to , pT2N0. Pathologic response correlated with improved
recurrence-free survival and overall survival. Nineteen patients (39%) required toxicity-related dose
modiﬁcations. Sixty-seven percent of patients completed all six planned cycles. No patient failed to
undergo RC as a result of chemotherapy-associated toxicities. The most frequent treatment-related
toxicity was anemia (12%; grade 3). The presence of a presumed deleterious DNA damage re-
sponse (DDR) gene alteration was associated with chemosensitivity (positive predictive value for
, pT2N0 [89%]). No patient with a deleterious DDR gene alteration has experienced recurrence at
a median follow-up of 2 years.
Conclusion
Six cycles of ddGC is an active, well-tolerated neoadjuvant regimen for the treatment of patientswith
MIBC. The presence of a putative deleterious DDR gene alteration in pretreatment tumor tissue
strongly predicted for chemosensitivity, durable response, and superior long-term survival.
J Clin Oncol 36:1949-1956. © 2018 by American Society of Clinical Oncology
INTRODUCTION
Randomized trials in patients with muscle-invasive
bladder cancer (MIBC) have established that neo-
adjuvant cisplatin-based chemotherapy before radical
cystectomy–pelvic lymph node dissection (RC-
PLND) improves long-term survival compared
with surgery alone, providing level 1 evidence that
supports multimodality management as a stan-
dard of care.1 A pivotal trial that used neoadjuvant
methotrexate, vinblastine, doxorubicin, and cis-
platin (M-VAC) demonstrated that three cycles of
chemotherapy over 12 weeks reduced the positive
surgical margin rate, did not compromise surgical
management, and could achieve pathologic down-
staging at RC-PLND, which was associated with
long-term survival.1 Subsequent trials modiﬁed the
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chemotherapy component via dose intensiﬁcation,2 increased dose
density,2-5 or by substituting newer cisplatin-based regimens, such as
gemcitabine and cisplatin (GC), using standard or increased dose
density and schedules.6,7 However, consensus is lacking with regard
to the optimal cisplatin regimen, drug dose, number of cycles, and
preoperative chemotherapy duration.
Neoadjuvant chemotherapy has been underused predomi-
nantly because of concerns that clinical beneﬁt is restricted to
a subset of patients while all patients are exposed to chemotherapy
toxicity.8 These concerns have prompted studies to identify the
patients who are most likely to beneﬁt from chemotherapy by
evaluating potential biomarkers that are predictive of chemo-
sensitivity.9-12 Next-generation sequencing (NGS), which facilitates
the genomic proﬁling of transurethral resection (TUR) specimens
and correlation with pathologic response and long-term survival,
has accelerated these efforts. In one study, mutations within the nu-
cleotide excision repair (NER) DNA helicase, ERCC2, were enriched
within patients who achieved a pathologic complete response (pT0)
or were downstaged to noninvasive disease after neoadjuvant che-
motherapy.10 Another study identiﬁed alterations within the DNA
damage response (DDR) genes, ATM, FANCC, and RB1, as associated
with heightened neoadjuvant chemosensitivity.11
We assessed the efﬁcacy of neoadjuvant dose-dense (dd) GC in
a multicenter phase II trial. This regimen was chosen on the basis of
a randomized trial that compared ddGC with ddM-VAC—both
administered for six cycles over 12 weeks—for the treatment of
patients with metastatic disease that showed similar survival but less
toxicity with ddGC. Moreover, the response rates and median
survival that were observed with both dose-dense regimens were
superior to results reported with standard-dose GC.13,14 The
gemcitabine dose (2,500 mg/m2) has been demonstrated to be well
tolerated in the metastatic setting in combination chemotherapy
regimens.15 The primary end point of the trial was pathologic response
rate—downstaging to non–muscle-invasive disease (, pT2)—with
secondary end points of safety and recurrence-free survival (RFS).
Patients’ bladders were serially imaged to identify the time to
maximal chemotherapy response. Pretreatment TUR specimens
were sequenced to validate previously identiﬁed, putative pre-
dictive biomarkers of chemosensitivity.
PATIENTS AND METHODS
Eligibility
Patients with clinical stage T2 to T4aN0M0 disease who were can-
didates for RC-PLND were enrolled. Cystoscopy with TUR was performed
within 60 days of enrollment for stage conﬁrmation. Whereas repeat TUR
at study sites was not required, pathologic conﬁrmation of MIBC was
mandated. Exam under anesthesia was encouraged to inform clinical
staging. Chest X-ray or chest computed tomography (CT) scan and a CT
scan or magnetic resonance imaging of the abdomen and pelvis—diffusion-
weighted magnetic resonance imaging preferred—were required within
30 days of enrollment. Cisplatin candidacy was deﬁned as an estimated
glomerular ﬁltration rate$ 60 mL/min per 1.73 m2 (Chronic Kidney Disease
Epidemiology Collaboration formula); Karnofsky performance status (KPS)
of $ 70%; and no pre-existing grade 2 peripheral neuropathy or hearing
impairment, New YorkHeart Association class III or IV heart failure, or recent
cardiovascular event.
This study was approved by the institutional review boards of par-
ticipating sites and performed in accordance with the Declaration of
Helsinki and Good Clinical Practice guidelines. All patients provided
written informed consent before study entry.
Procedures
This was a nonrandomized, multi-institutional, open-label phase II
study. Patients received six 14-day cycles of ddGC: gemcitabine 2,500 mg/m2
on day 1, cisplatin 35 mg/m2 on days 1 and 2 (achieving a planned dose
intensity of 1.875 times and 1.5 times standard gemcitabine and cisplatin,
respectively), and pegﬁlgrastim on day 3. Intravenous mannitol was ad-
ministered precisplatin. Intravenous hydration and antiemetics were ad-
ministered according to institutional guidelines.
Clinical Assessment
Patients underwent a history, physical examination, and toxicity
assessment using National Cancer Institute Common Terminology Criteria
for Adverse Events (version 4.0) on day 1 of each cycle. Imaging was
performed after four and six chemotherapy cycles. RC-PLND was rec-
ommended within 4 to 8 weeks after completing chemotherapy.
Correlative Assessments
Radiographic features of primary bladder tumors were compared
between baseline and postcycles 4 and 6 scans (Data Supplement).
NGS using the Integrated Mutation Proﬁling of Actionable Cancer
Targets platform was performed as previously described using DNA from
pretreatment TUR and matched normal specimens (Data Supplement).16
Mutation status of 29 DDR genes—selected post hoc—was correlated with
response (Data Supplement). Genes were chosen on the basis of their
presence within canonical DDR pathways, a reported association with
chemosensitivity in urothelial carcinoma (UC), or those genes altered
signiﬁcantly within The Cancer Genome Atlas (TCGA) for urothelial
bladder carcinoma.
Statistical Analysis
The primary end point was pathologic response to neoadjuvant
ddGC, which was deﬁned as the absence of muscle-invasive disease (, pT2)
and lymph node metastases (N0) within the RC-PLND specimen as
assessed by institutional pathologists using the American Joint Committee
on Cancer 7th edition criteria.17 Null hypothesis pathologic response rate
was 35% on the basis of a retrospective study of standard-dose neoadjuvant
GC and two prospective randomized trials.1,6,18 A response rate im-
provement from 35% to 55% was considered promising. Patients who
developed progressive metastatic disease on chemotherapy or who were
unable to or refused to undergo RC-PLNDwere considered nonresponders
for the primary end point analysis. Patients who received fewer than three
cycles of chemotherapy were inevaluable for the primary end point and
replaced. If 22 or more of 46 evaluable patients were , pT2N0, then the
treatment regimen would be considered worthy of additional study. The
study design was based on an exact binomial one-sided test with a type I
error of 5% and power of 87%.
The secondary end point of RFS was assessed using the Kaplan-Meier
method and measured from treatment initiation until disease recurrence,
which was deﬁned as clinically or radiographically documented pro-
gression before RC-PLND, or local or metastatic recurrence after RC-
PLND. Patients without documented recurrence were censored at last
follow-up. Pathologic response and DDR mutation status were cor-
related with survival using a log-rank test. In these analyses, RFS was
measured from RC-PLND to the date of disease recurrence. Association
between response and DDR mutation status was analyzed using a one-
sided Fisher exact test as the direction of the potential effect was de-
termined on the basis of previous ﬁndings. Mutation burden between
responders and nonresponders was tested using the Mann-Whitney
test.
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RESULTS
Forty-nine patients—40 male and nine female—were enrolled
between June 2012 and July 2015 (Table 1). Median Karnofsky
performance status was 90% and median age 64 years. Thirty-four
percent of patients had cT3 to 4 disease at enrollment. Three patients
who received two or fewer cycles of chemotherapy—one experi-
enced a vascular access complication, and two patients had elevated
creatinine levels that precluded safe cisplatin administration—were
inevaluable for the primary end point and were replaced.
Of 49 patients, 19 (39%) required toxicity-related dose modi-
ﬁcations or early treatment discontinuation. Dose delays or re-
ductions were predominantly a result of thrombocytopenia (18%)
and creatinine elevation (6%). Treatment-related grade 3 and 4
toxicity occurred in 37% of patients (Table 2). The most common
toxicity was anemia (12%; grade 3). The most common non-
hematologic toxicity was hyperglycemia (39% [grades 1 and 2] and
12% [grades 3 and 4]). The thromboembolic event rate—arterial or
venous—was 6%, which occurred during chemotherapy. The median
number of days from the completion of ddGC to RC-PLND was 45
(range, 30 to 78 days). No patient failed to undergoRC-PLNDas a result
of treatment toxicity. Eight patients underwent RC-PLND. 8 weeks
after ddGC completion secondary to scheduling availability.
Forty-six of 49 patients were evaluable for the primary end
point. The study met the primary end point with a pathologic
response rate of 57% (95%CI, 42% to 70%) with 26 responders. In
an exploratory, intent-to-treat analysis of all patients, the response
rate was 53% (26 of 49 patients; 95%CI, 0.39 to 0.66). Five patients
who completed three or more cycles did not undergo RC and were
designated nonresponders—one refused surgery, one developed
metastatic progression after four cycles, one withdrew consent, one
was lost to follow-up, and one patient was incidentally diagnosed
with moyamoya and discontinued the study because of the risk for
vascular thrombotic events. Among the 41 patients who underwent
RC and the patient who experienced progression with metastatic
disease during therapy, pathologic response rate was 62% (95% CI,
48% to 76%), including 21 patients who were downstaged to
, pT1 (Table 3). pT0 rate was 15% (95% CI, 0.08 to 0.28). The
median number of nodes retrieved at RC was 24 (range, four to 56
nodes), and two patients had N1 disease. Median RFS and overall
survival were not reached at a median follow-up for living patients
of 25.6 months (Figs 1A and 1B). Among 46 eligible patients, nine
have died (seven from disease), and eight have experienced disease
progression. Of 41 patients who underwent RC, chemotherapy
responders (, pT2N0) had signiﬁcantly better RFS compared with
nonresponders ($ pT2N0 disease; hazard ratio, 0.088; 95% CI,
0.01 to 0.73; log rank P = .004; Fig 2A). The 2-year RFS rate
responders and nonresponders was 96% and 52%, respectively,
and the 2-year overall survival rate for responders versus
nonresponders was 96% and 84%, respectively (hazard ratio, 0.15;
95% CI, 0.02 to 1.26; log-rank P = .043; Fig 2B).
Twenty-seven patients (59%) were evaluable for comparison of
imaging of the primary bladder tumor pretreatment, postcycle 4, and
postcycle 6 (Data Supplement). Twenty-four patients demonstrated
an evaluable primary tumormass and/or bladder wall thickening that
was consistent with residual disease after four cycles. Ten patients had
an additional reduction of the radiographic lesion on the scan
obtained after cycle 6 (42%). Nine of 10 patients underwent
RC-PLND, and seven of nine patients exhibited downstaging of
disease postchemotherapy. Of the remaining 14 patients, nine had
a reduction in lesions after four cycles, but not after six cycles, and
seven of nine patients had corresponding pathologic downstaging.
Adequate pretreatment tumor and germline DNA was
available for NGS analyses in 32 patients, including those who
received three or more cycles of ddGC followed by RC-PLND and
one patient who experienced progression systemically during
chemotherapy. For one patient, matched germline DNA was un-
available and a pooled normal control was used. Missense variants
reported in dbSNP or the 1000 Genomes project were excluded for
this sample. Median tumor and germline coverage were 691X and
467X, respectively. Somatic alterations identiﬁed per tumor sample
are listed in the Data Supplement. Frequency and type of somatic
alterations resembled the urothelial TCGA (Data Supplement),
except for the TERT promoter region (not sequenced in TCGA).
Alterations within a panel of 29 DDR genes were correlated with
chemotherapy response. Deleterious DDR gene alterations, which
were deﬁned as nonsense, frameshift, or splice site alterations, or
ERCC2 missense mutations, were identiﬁed in nine patients, with
ERCC2mutations being most common (n = 4). Eight of these nine
patients were chemotherapy responders (Fig 3A). The positive
predictive value of a somatic deleterious DDR gene alteration for
response was 89%, and 2-year RFS was higher in patients whose
tumors had a deleterious DDR gene alteration compared with
those without an alteration (100% v 61%; log-rank P = .07; Fig 3B).
Deleterious DDR gene–altered tumors have been associated
with a higher mutation burden.19,20 In this study, patients with
a deleterious DDR gene alteration had a higher mutation burden
than did patients without an alteration, regardless of response
status (median 15.2 mutations v 5.8 mutations/megabase; P, .01);
however, mutation burden between responders and non-
responders was not statistically signiﬁcant (median 7.9 mutations v
9.4 mutations/megabase; P = .6; Fig 3C).
DISCUSSION
The current study sought to maximize GC dose density and to
explore six cycles of neoadjuvant chemotherapy using a dose and
Table 1. Patient Demographics and Clinical Characteristics (N = 49)
Parameter No. (%)
Median age (range) 64 (37-78)
Sex
Male 40 (82)
Female 9 (18)
Tobacco use
Current 6 (12)
Former 32 (65)
Never 11 (22)
Median KPS (range) 90 (80-100)
Clinical T stage at presentation
T2N0 32 (65)
T3N0 12 (25)
T4aN0 5 (10)
Abbreviation: KPS, Karnofsky performance status.
jco.org © 2018 by American Society of Clinical Oncology 1951
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schedule that demonstrated encouraging clinical outcomes
for patients with metastatic disease. With a pathologic response
rate of 57%, the study met its primary end point. The regimen
delivered twice the total cisplatin dose density that was intended
in SWOG 8710, which used standard-dose M-VAC. This im-
provement in drug delivery is relevant as UC trials have con-
sistently shown that dose-dense chemotherapy is associated
with higher response rates in neoadjuvant and metastatic
settings.3-5,13 Whereas grades 3 and 4 toxicity were observed in
37% of patients, no patient experienced toxicity-related delays to
RC-PLND.
The 57% pathologic response rate is comparable to other
dose-dense neoadjuvant regimens (49% to 53% , pT2 rate).4,5
Whereas the pT0 rate was lower (15%) than that reported in other
neoadjuvant studies, we have shown that patients with pT0
and those with , pT2 responses have a similar 5-year survival
of . 90%.21 Moreover, , pT2 is the primary efﬁcacy end point
in an ongoing intergroup neoadjuvant trial (SWOG S1314).
Finally, although the pathologic response rate in patients who
underwent RC-PLND was not a prespeciﬁed end point, the 62%
rate of downstaging to , pT2 and the improved survival rate
within this patient population underscores the efﬁcacy of the
ddGC regimen.
A controversial aspect of this trial was the use of six cycles of
neoadjuvant chemotherapy; the optimal number of cycles has
never been formally studied. Limiting treatment to three to four
cycles originated empirically from concerns that potentially in-
effective chemotherapy might delay curative surgery. Of 49 pa-
tients, 33 (67%) completed all six cycles, which allowed for the
assessment of the relationship between cycle number and efﬁcacy.
Ten of 24 patients exhibited continued reduction of a radiographic
abnormality between four and six cycles, and seven patients
achieved downstaging from pretreatment clinical stage. In addi-
tion, only 4% of patients (two of 41) who underwent RC-PLND
had metastatic node involvement—a median of 24 nodes retrie-
ved—compared with a node-positive rate between 21% and 26%
in retrospective analyses of standard neoadjuvant GC.21 These
ﬁndings challenge the paradigm of three to four cycles as the
standard for neoadjuvant treatment.
The higher than normal gemcitabine dose (2,500 mg/m2) se-
lected for this study, although it was based on a previous randomized
trial, is controversial. From a pharmacokinetics perspective, the
plasma area under the concentration-time curve of gemcitabine in-
creases linearly from 40 mg/m2 to 3,650 mg/m2, and its predominant
active and inactive metabolites—29, 29-diﬂuoro-29-deoxycytidine
triphosphate (dFdCTP) and 29, 29-diﬂuorodeoxyuridine (dFdU),
respectively—also display linear area under the concentration-time
curve relationships with higher doses.22,23 Both dFdCTP and dFdU
are also cytotoxic. Conversely, human studies that validate higher
intratumoral concentrations of gemcitabine and its metabolites with
higher administered doses are currently lacking. Multiple groups have
reported venous thromboembolism rates of 13% to 18% in patients
who receive cisplatin-based chemotherapy.24 In another trial of
neoadjuvant ddGC, two of the ﬁrst 13 enrolled patients experienced
a myocardial infarction and two had venous thromboembolic events,
Table 3. Pathologic Response at Radical Cystectomy
Pathologic Response No.
, pT2N0 (26)
T0 7
Ta 1
CIS 13
T1 5
$ pT2N0 (13)
T2 7
T3 6
Node positive
T2bN1 2
Table 2. Treatment-Related Toxicities Occurring During Chemotherapy and
Within 30 Days of Radical Cystectomy
Adverse Event
Grade
1 and 2
3 and 4
Pre-RC Post-RC
Hematologic
Anemia 44 (90) 6 (12) 5 (12)
Platelet count decreased 33 (67) 3 (6)
Lymphocyte count decreased 6 (12) 2 (4) 2 (5)
Nonhematologic
Hyperglycemia 19 (39) 3 (6)
Vomiting 10 (20) 2 (4)
Fatigue 41 (84) 1 (2)
Nausea 32 (65) 1 (2)
Hypomagnesemia 20 (41) 1 (2)
Hypocalcemia 16 (33) 1 (2)
Creatinine increased 15 (31) 1 (2)
Headache 11 (22) 1 (2)
Anorexia 7 (14) 1 (2)
Hypokalemia 6 (12) 1 (2)
Hypertension 4 (8) 1 (2)
Vascular access complication* 1 (2) 1 (2)
Dehydration 2 (4) 1 (2)
Syncope 1 (2) 1 (2)
Heart Failure 1 (2) 1 (2)
Alkaline phosphatase increased 27 (55)
Alopecia 20 (41)
Constipation 18 (37)
Hypoalbuminemia 15 (31)
Peripheral sensory neuropathy 14 (29)
Tinnitus 14 (29)
Dysgeusia 11 (22)
Aspartate aminotransferase increased 9 (18)
Mucositis, oral 9 (18)
Dyspnea 9 (18)
Diarrhea 7 (14)
Alanine aminotransferase increased 6 (12)
Hyponatremia 5 (10)
Rash, maculo-papular 5 (10)
Cystitis, noninfective 3 (6)
Hyperkalemia 3 (6)
Blood bilirubin increased 3 (6)
Back pain 3 (6)
Infection 2 (4)
Hypophosphatemia 2 (4)
Urinary frequency 2 (4)
Hypernatremia 2 (4)
NOTE. Data are presented as No. (%) unless otherwise noted.
Abbreviation: RC, radical cystectomy.
*Two patients had vascular access complications: one patient had an
improperly positioned Mediport that resulted in drug extravasation, and
one patient refused C6D2 of chemotherapy as a result of difﬁculty obtaining
access secondary to peripheral vein sclerosis.
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with an overall 9% incidence of grades 3 and 4 vascular events.7 In that
study, cisplatin 70 mg/m2 was administered on day 1. We did not
observe a higher than anticipated rate of thromboembolic events (6%)
in this study, whichmay be related to splitting cisplatin over days 1 and
2 and the upfront exclusion of patients who had experienced car-
diovascular events or who had a history of angina or stroke within
6 months of chemotherapy administration. The possibility for sig-
niﬁcant toxicities that preclude potentially curative RC-PLND un-
derscores the need to identify predictive biomarkers of neoadjuvant
chemosensitivity.
Published retrospective studies suggest that deleterious al-
terations in DDR genes might represent predictive biomarkers
of chemosensitivity. In this study, eight of nine patients whose
tumors harbored a putative, loss-of-function DDR gene alteration
exhibited either a pathologic complete response or downstaging
to, pT1 at RC-PLND. To date, no patient with a deleterious DDR
gene alteration has experienced a metastatic recurrence, including
the CHEK2 mutant nonresponder. Whereas the NER pathway was
most frequently altered, several other DDR pathway genes had
potentially deleterious alterations, including BRCA2 and RAD51C
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(homologous recombination), ATR and CHEK2 (DNA damage
sensing), and RECQL4 (double-strand break repair), and correlated
with chemosensitivity. The association between high mutation
burden and deleterious DDR gene alterations is in agreement with
other studies that correlated the disruption of key DDR pathways
with increased genomic instability. It highlights the need for
a stringent deﬁnition for loss-of-function DDR gene alterations to
discriminate known or likely deleterious mutations from passenger
events and the need for functional validation of such alterations.25
Finally, most responders (62%) did not harbor deleterious DDR
gene alterations, which suggest that additional factors affect che-
mosensitivity. SWOG S1314 is examining the use of gene expression
proﬁling to predict for neoadjuvant chemotherapy response. These
data may provide validation for our ﬁndings and identify novel bio-
markers of chemosensitivity in DDR pathway wild-type responders.
Limitations of our study include the lack of a comparator arm
and the relatively small sample size. Moreover, potentially dele-
terious DDR gene alterations were analyzed together. Larger
studies are needed to determine whether chemosensitivity varies
on the basis of speciﬁc mutant alleles within individual genes or
which DDR gene is mutated. Unbiased genomic proﬁling—not
feasible because of limited tumor tissue—may have identiﬁed
additional putative biomarkers of chemosensitivity, particularly in
DDR gene wild-type patients. Such proﬁling could also detect and
correlate genome-wide mutation signatures with response, in-
cluding the APOBEC signature, homologous recombination de-
ﬁciency signatures that are associated with BRCA1/2 functional
impairment, or the signature 5*, which is associated with ERCC2
alterations and NER deﬁciency.26-28 Moreover, whereas germline
DNA was used to delineate somatic alterations, this study did not
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Fig 3. (A) Onco-print showing the alterations identiﬁed in 32 pretreatment transurethral resection specimens from patients who underwent radical cystectomy (RC) –pelvic
lymph node dissection after treatment with dose-dense gemcitabine and cisplatin. Samples are organized into responders or nonresponders with mutation burden
displayed for each sample. (Top) Alterations within DNA damage response (DDR) genes. (Bottom) Alterations within the top 10 most frequently altered genes within this
tumor cohort. (B) Two-year recurrence-free survival (RFS) in patients with or without DDRmutant tumors (DDR mut [mutant] v DDR wt [wild type]). (C) Mutation burden in
responders versus nonresponders and in any patient with deleterious DDR gene alterations (Del DDRmut+) compared with those without (Del DDRmut-). Mb, megabase.
(*)P , .05.
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include consent to review this data for potential heritable alter-
ations that could confer cisplatin chemosensitivity as observed in
other tumor types.29-31
The concept of organ sparing has been adopted for the
management of breast, rectal, and laryngeal cancers,32,33 but not
MIBC, despite the fact that RC-PLND signiﬁcantly affects body
image and quality of life.34 Trimodality bladder sparing, which
consists of chemoradiation after a maximal TUR, results in fa-
vorable outcomes for highly selected patients but is associated with
local toxicities, and up to 29% of patients may ultimately require
RC-PLND.35 Retrospective data from three institutions indicate
that patients with MIBC who achieve a clinical complete response
to neoadjuvant chemotherapy can be managed with surveillance
without RC-PLND.36-38 The 10-year survival for patients from two
of these institutions was 68% to 75%, with a bladder-intact survival
rate of 47% to 61%. A reﬁnement of this approachmay be possible:
Prospective detection of deleterious DDR gene alterations may
allow for the selection of patients who are most likely to expe-
rience durable responses to chemotherapy through eradication of
bladder-conﬁned and micrometastatic disease. TUR plus deﬁnitive
chemotherapy may sufﬁce for patients with deleterious DDR gene
alterations who display exquisite chemosensitivity. Bladder pres-
ervation is reasonable in this context as six cycles of ddGC can cure
patients with metastatic disease, with a median survival that is
more favorable than reported with standard-dose therapy. These
results challenge the orthodoxy that bladder extirpation is required
for all patients with MIBC. Consequently, the Alliance trial A031701
will test this concept prospectively using neoadjuvant ddGC in
MIBC, performing real-time genomic proﬁling, and offering
bladder preservation in responding patients with deleterious DDR
gene alterations.
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